<DOC>
	<DOC>NCT02956278</DOC>
	<brief_summary>Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.</brief_summary>
	<brief_title>The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>selfidentified as Asian/European ancestry generally healthy with approved lab values for CBC,HFP,RFP, and uric acid Subjects with the ABCG2 genotype, homozygous, heterozygous or homozygous for the major allele of rs2231142 will be recruited vascular disease renal impairment medications/supplements that affect uric acid levels pregnant or lactating women prior history of allergic reaction to allopurinol or testing positive for HLAB*5801 allele risk of urinary or gastric retention or narrowangle glaucoma impaired hepatic function evidence of anemia evidence or diagnosis of congestive heart failure smokers subjects with a mutation other than rs2231142 in the ABCG2 genotype subjects taking hormonal contraceptives or other hormonal medications evidence of recreational drug use as determined by questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>allopurinol</keyword>
</DOC>